iOnctura exercises exclusive global option to license two of Cancer Research UK’s projects

iOnctura SA is delighted to announce today that it has exercised its exclusive global option to license two of Cancer Research UK’s projects, which are the result of a successful strategic alliance programme with CRUK-Therapeutic Discovery Labs (TDL). Under the terms of the licence agreements iOnctura will be solely responsible for the development and commercialisation of an IND stage autotaxin inhibitor and a preclinical stage anti-CD73 antibody.

These projects have been successfully co-developed from early stage research to lead optimisation. CRUK’s contribution was crucial to the success of the alliance: TDL scientists led the experiments and provided intellectual advice, while the programme was overseen by both business development and strategic alliance managers.

By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.

GET IN TOUCH